Skip to main content
PMC home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1987 Oct;25(10):1868–1874. doi: 10.1128/jcm.25.10.1868-1874.1987

Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis.

A E Hollsing 1, M Granström 1, M L Vasil 1, B Wretlind 1, B Strandvik 1
PMCID: PMC269358  PMID: 3117842

Abstract

Serum immunoglobulin G to four purified antigens from Pseudomonas aeruginosa, phospholipase C, alkaline protease, exotoxin A, and elastase, were determined in 62 patients with cystic fibrosis by enzyme-linked immunosorbent assay. The patients were followed for 12 to 24 months in a prospective study. Increased titers, i.e., titers more than 2 standard deviations above those of normal controls, were exclusively found in patients chronically colonized with P. aeruginosa and not in patients harboring only Staphylococcus aureus. The frequencies of elevated titers of antibody to the different antigens varied from 100% (phospholipase C) to 58% (alkaline protease and exotoxin A) to 15% (elastase) in the chronically colonized patients. Mean serum titer levels, expressed as multiples of the age-correlated upper normal limit (=1), were significantly higher to phospholipase C in patients with dual colonization with P. aeruginosa and S. aureus than in those colonized only with P. aeruginosa (P less than 0.001). Conversely, the other three antigens showed significantly higher serum antibody titer levels in patients harboring only P. aeruginosa (P less than 0.001). In five patients who became colonized with P. aeruginosa during the study period, serum antibodies to phospholipase C and exotoxin A increased first. Exceptions to the general pattern of antibody responses were found in three patients chronically colonized with Escherichia coli. They showed a delayed enhancement of anti-phospholipase C titers after the chronic P. aeruginosa colonization. Serum titers were not influenced by exacerbations of pulmonary infection or by antimicrobial therapy. The determination of titers of serum antibody to phospholipase C seems to be a valuable indicator of a chronic colonization with P. aeruginosa. The results further suggest that bacterial metabolism and interactions may influence the antibody response.

Full text

PDF
1868

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berka R. M., Vasil M. L. Phospholipase C (heat-labile hemolysin) of Pseudomonas aeruginosa: purification and preliminary characterization. J Bacteriol. 1982 Oct;152(1):239–245. doi: 10.1128/jb.152.1.239-245.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bjorn M. J., Sokol P. A., Iglewski B. H. Influence of iron on yields of extracellular products in Pseudomonas aeruginosa cultures. J Bacteriol. 1979 Apr;138(1):193–200. doi: 10.1128/jb.138.1.193-200.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brett M. M., Ghoneim A. T., Littlewood J. M. Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis. Arch Dis Child. 1986 Nov;61(11):1114–1120. doi: 10.1136/adc.61.11.1114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Döring G., Høiby N. Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis. Infect Immun. 1983 Oct;42(1):197–201. doi: 10.1128/iai.42.1.197-201.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. ENGSTROM I., KARLBERG P., SWARTS C. L. Respiratory studies in children. IX. Relationships between mechanical properties of the lungs, lung volumes and ventilatory capacity in healthy children 7-15 years of age. Acta Paediatr. 1962 Jan;51:68–80. doi: 10.1111/j.1651-2227.1962.tb06511.x. [DOI] [PubMed] [Google Scholar]
  6. Ericsson A., Granström M., Möllby R., Strandvik B. Antibodies to staphylococcal teichoic acid and alpha toxin in patients with cystic fibrosis. Acta Paediatr Scand. 1986 Jan;75(1):139–144. doi: 10.1111/j.1651-2227.1986.tb10170.x. [DOI] [PubMed] [Google Scholar]
  7. Gilljam H., Malmborg A. S., Strandvik B. Conformity of bacterial growth in sputum and contamination free endobronchial samples in patients with cystic fibrosis. Thorax. 1986 Aug;41(8):641–646. doi: 10.1136/thx.41.8.641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Granström M., Ericsson A., Strandvik B., Wretlind B., Pavlovskis O. R., Berka R., Vasil M. L. Relation between antibody response to Pseudomonas aeruginosa exoproteins and colonization/infection in patients with cystic fibrosis. Acta Paediatr Scand. 1984 Nov;73(6):772–777. doi: 10.1111/j.1651-2227.1984.tb17774.x. [DOI] [PubMed] [Google Scholar]
  9. Granström M., Wretlind B., Markman B., Pavlovskis O. R., Vasil M. L. Enzyme-linked immunosorbent assay for detection of antibodies to Pseudomonas aeruginosa exoproteins. Eur J Clin Microbiol. 1985 Apr;4(2):197–200. doi: 10.1007/BF02013597. [DOI] [PubMed] [Google Scholar]
  10. Hastie A. T., Hingley S. T., Kueppers F., Higgins M. L., Tannenbaum C. S., Weinbaum G. Protease production by Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Infect Immun. 1983 May;40(2):506–513. doi: 10.1128/iai.40.2.506-513.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hoiby N., Flensborg E. W., Beck B., Friis B., Jacobsen S. V., Jacobsen L. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. Scand J Respir Dis. 1977 Apr;58(2):65–79. [PubMed] [Google Scholar]
  12. Jagger K. S., Bahner D. R., Warren R. L. Protease phenotypes of Pseudomonas aeruginosa isolated from patients with cystic fibrosis. J Clin Microbiol. 1983 Jan;17(1):55–59. doi: 10.1128/jcm.17.1.55-59.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jagger K. S., Robinson D. L., Franz M. N., Warren R. L. Detection by enzyme-linked immunosorbent assays of antibody specific for Pseudomonas proteases and exotoxin A in sera from cystic fibrosis patients. J Clin Microbiol. 1982 Jun;15(6):1054–1058. doi: 10.1128/jcm.15.6.1054-1058.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kelly H. W., Lovato C. Antibiotic use in cystic fibrosis. Drug Intell Clin Pharm. 1984 Oct;18(10):772–783. doi: 10.1177/106002808401801001. [DOI] [PubMed] [Google Scholar]
  15. Klinger J. D., Straus D. C., Hilton C. B., Bass J. A. Antibodies to proteases and exotoxin A of Pseudomonas aeruginosa in patients with cystic fibrosis: Demonstration by radioimmunoassay. J Infect Dis. 1978 Jul;138(1):49–48. doi: 10.1093/infdis/138.1.49. [DOI] [PubMed] [Google Scholar]
  16. Klinger K. W., Shuster C. W., Klinger J. Reaction of antibody in sera from cystic fibrosis patients with non-toxic forms of Pseudomonas aeruginosa exotoxin A. Eur J Clin Microbiol. 1985 Apr;4(2):201–206. doi: 10.1007/BF02013598. [DOI] [PubMed] [Google Scholar]
  17. Kusoffsky E., Strandvik B., Troell S. Prospective study of fatty acid supplementation over 3 years in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 1983;2(3):434–438. doi: 10.1097/00005176-198302030-00007. [DOI] [PubMed] [Google Scholar]
  18. Luzar M. A., Montie T. C. Avirulence and altered physiological properties of cystic fibrosis strains of Pseudomonas aeruginosa. Infect Immun. 1985 Nov;50(2):572–576. doi: 10.1128/iai.50.2.572-576.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Marks M. I. The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis. J Pediatr. 1981 Feb;98(2):173–179. doi: 10.1016/s0022-3476(81)80631-2. [DOI] [PubMed] [Google Scholar]
  20. Matthews L. W., Drotar D. Cystic fibrosis--a challenging long-term chronic disease. Pediatr Clin North Am. 1984 Feb;31(1):133–152. doi: 10.1016/s0031-3955(16)34541-2. [DOI] [PubMed] [Google Scholar]
  21. Müller H., Kettelhack C., Kettelhack M., Sonntag H. G., Keilich G., Brossmer R., Richards J., Kinzel V., Bäuerlein E., Pech H. Variation and adaptation of Pseudomonas aeruginosa toxicity to HeLa cells and fibroblasts. J Clin Microbiol. 1986 Sep;24(3):317–323. doi: 10.1128/jcm.24.3.317-323.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Nelson J. D. Management of acute pulmonary exacerbations in cystic fibrosis: a critical appraisal. J Pediatr. 1985 Jun;106(6):1030–1034. doi: 10.1016/s0022-3476(85)80264-x. [DOI] [PubMed] [Google Scholar]
  23. Pier G. B. Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction. J Infect Dis. 1985 Apr;151(4):575–580. doi: 10.1093/infdis/151.4.575. [DOI] [PubMed] [Google Scholar]
  24. Pitt T. L. Biology of Pseudomonas aeruginosa in relation to pulmonary infection in cystic fibrosis. J R Soc Med. 1986;79 (Suppl 12):13–18. [PMC free article] [PubMed] [Google Scholar]
  25. SHWACHMAN H., KULCZYCKI L. L. Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period. AMA J Dis Child. 1958 Jul;96(1):6–15. doi: 10.1001/archpedi.1958.02060060008002. [DOI] [PubMed] [Google Scholar]
  26. Strandvik B., Malmborg A. S., Alfredson H., Ericsson A. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):283–287. doi: 10.1093/jac/12.suppl_a.283. [DOI] [PubMed] [Google Scholar]
  27. Vasil M. L., Berka R. M., Gray G. L., Pavlovskis O. R. Biochemical and genetic studies of iron-regulated (exotoxin A) and phosphate-regulated (hemolysin phospholipase C) virulence factors of Pseudomonas aeruginosa. Antibiot Chemother (1971) 1985;36:23–39. doi: 10.1159/000410469. [DOI] [PubMed] [Google Scholar]
  28. Vasil M. L. Pseudomonas aeruginosa: biology, mechanisms of virulence, epidemiology. J Pediatr. 1986 May;108(5 Pt 2):800–805. doi: 10.1016/s0022-3476(86)80748-x. [DOI] [PubMed] [Google Scholar]
  29. Verbrugh H. A., Peters R., Goessens W. H., Michel M. F. Distinguishing complicated from uncomplicated bacteremia caused by Staphylococcus aureus: the value of "new" and "old" serological tests. J Infect Dis. 1986 Jan;153(1):109–115. doi: 10.1093/infdis/153.1.109. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES